Jiuquan, China, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the “Company”) (Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, today announced the closing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share.
Read the rest here:
Qilian International Holding Group Limited Announces Closing of Initial Public Offering
Related Post
- Neuronetics Names Cory Anderson Vice President, Clinical Affairs and Medical Operations - March 3rd, 2021
- TCR² Therapeutics to Participate in Two Upcoming Conferences in March - March 3rd, 2021
- Market Report Bodes Well for Reflect Scientific Growth Potential - March 3rd, 2021
- Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81% - March 3rd, 2021
- Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonists Show Significant Reduction in Binge Eating - March 3rd, 2021
- Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty - March 3rd, 2021
- Cognition Therapeutics to Present Corporate and Clinical Update at H.C. Wainwright Global Life Sciences Conference - March 3rd, 2021
- Arbor Biotechnologies Names Mark D. Angelino to its Board of Directors - March 3rd, 2021
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences - March 3rd, 2021
- Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference - March 3rd, 2021
- Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference - March 3rd, 2021
- Tricida Granted Additional U.S. Patent Covering Composition of Matter of Veverimer - March 3rd, 2021
- Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full-Year 2020 Financial Results on Thursday, March 11, 2021 - March 3rd, 2021
- Vir Biotechnology and GSK Provide Update on NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19 - March 3rd, 2021
- Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference - March 3rd, 2021
- Notice to convene Annual General Meeting - March 3rd, 2021
- Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference - March 3rd, 2021
- Ceapro Inc. to Present at the H.C. Wainwright Global Life Sciences Conference - March 3rd, 2021
- 22nd Century Group Secures Exclusive Agreement with CannaMetrix to Accelerate Commercialization of New, Disruptive Hemp/Cannabis Plant Lines and... - March 3rd, 2021
- SetPoint Medical CEO Murthy Simhambhatla Named to AIMBE College of Fellows - March 3rd, 2021
- EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19 - March 1st, 2021
- Ascendis Pharma A/S Announces New “Outgrow GHD” Educational Resource to Support Rare Disease Day 2021 - March 1st, 2021
- MacroGenics to Participate in Upcoming Investor Conferences - March 1st, 2021
- Cronos Group Reports 2020 Fourth Quarter and Full-Year Results - March 1st, 2021
- GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX® (cannabidiol) for use as treatment of seizures associated with Tuberous Sclerosis... - March 1st, 2021
- Golden Leaf Holdings Enters into Letter of Intent to Acquire Retail Chain - March 1st, 2021
- TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update - March 1st, 2021
- Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B... - March 1st, 2021
- Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® - March 1st, 2021
- SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results - March 1st, 2021
- Molecular Templates to Participate in Upcoming Virtual Investor Conferences - March 1st, 2021
- ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American... - March 1st, 2021
- electroCore Inc. Announces Exclusive Distribution Agreement with Medistar Following Regulatory Approval in Australia - March 1st, 2021
- BridgeBio Pharma and Affiliate Origin Biosciences Announce FDA Approval of NULIBRY™ (fosdenopterin), the First and Only Approved Therapy to Reduce... - March 1st, 2021
- Annual financial report 2020 - March 1st, 2021
- Idorsia submits NDA for clazosentan to Japanese PMDA - March 1st, 2021
- Santhera Announces Positive Results with Lonodelestat in Early Phase Cystic Fibrosis Trial - March 1st, 2021
- Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China - March 1st, 2021
- Orphazyme appoints Christophe Bourdon as Chief Executive Officer - March 1st, 2021
- Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day® - February 27th, 2021
- Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer - February 27th, 2021
- Albireo Spotlights Global Patient Communities on Rare Disease Day - February 27th, 2021
- Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda Initiates Phase 1/2 Trial in Japan - February 27th, 2021
- Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE - February 27th, 2021
- Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients - February 27th, 2021
- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization... - February 27th, 2021
- Genetic Technologies Limited Interview to Air on Bloomberg TV in the US on the RedChip Money Report® - February 27th, 2021
- Supernus to Present at Cowen Healthcare Conference - February 27th, 2021
- Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients - February 27th, 2021
- Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany - February 27th, 2021
- UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use... - February 27th, 2021
- GENFIT: Revenues and Cash Position as of December 31, 2020 - February 27th, 2021
- Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab - February 27th, 2021
- Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences - February 27th, 2021
- Orphazyme announces participation in upcoming virtual investor conferences - February 27th, 2021
- NextCure to Host Virtual R&D Update Event on March 4, 2021 - February 27th, 2021
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons - February 27th, 2021
- Zomedica Corp. Announces Year End 2020 Financial Results - February 27th, 2021
- Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights - February 27th, 2021
- Quotient Limited Announces Manuel Mendez as Chief Executive Officer - February 23rd, 2021
- AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer - February 23rd, 2021
- Notice for the Annual General Meeting of Novo Nordisk A/S - February 23rd, 2021
- Agios to Present at March Investor Conferences - February 23rd, 2021
- Recro Announces Amendment to Athyrium Credit Facility - February 23rd, 2021
- Coya Therapeutics™ Announces Formation of Scientific Advisory Board - February 23rd, 2021
- Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences - February 23rd, 2021
- Kraig Biocraft Laboratories receives its first-ever Spider Silk shipment from its Vietnamese production facility - February 23rd, 2021
- iTeos to Present at Upcoming Investor Conferences in March - February 23rd, 2021
- Study Demonstrates Macrolide-Resistance in S. pneumoniae in the United States Exceeds 25 Percent Threshold Set in Current Community-Acquired Bacterial... - February 23rd, 2021
- BioXcel Therapeutics Appoints Javier Rodriguez as Chief Legal Officer and Corporate Secretary - February 23rd, 2021
- Cerevel Therapeutics to Present at the Cowen 41st Annual Health Care Conference - February 23rd, 2021
- PolyPid to Participate in Upcoming Investor Conferences - February 23rd, 2021
- AgraFlora Organics Announces anticipated First Sales and Revenue for Summer 2021 - February 23rd, 2021
- Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection - February 23rd, 2021
- Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021 - February 23rd, 2021
- Black Diamond Therapeutics to Present at Upcoming Investor Conferences - February 23rd, 2021
- Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference - February 23rd, 2021
- European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis... - February 23rd, 2021
- TG Therapeutics Announces Publication of Final Results from the Phase 3 GENUINE Trial Evaluating Ublituximab Plus Ibrutinib in Patients with... - February 23rd, 2021
- GBT Announces Participation in Upcoming Investor Conferences - February 21st, 2021
Recent Comments